Long-acting, reversible and permanent methods of contraception: insight into women’s choice of method by Kane, Roslyn et al.
Research paper
Long-acting, reversible and permanent
methods of contraception: insight into
women’s choice of method
Roslyn Kane PhD MSc BSc RGN
Senior Lecturer, Faculty of Health Life and Social Sciences, University of Lincoln, UK
Gwen Irving MSc BA (Hons)
SSC Development Manager, The Hull York Medical School; previously Research Associate, Department
of Obstetrics and Gynaecology, University of Hull, UK
Sally Brown PhD MA LLB
Research Fellow, York Management School, University of York; previously Research Associate,
Department of Public Health and Primary Care, University of Hull, UK
Neal Parkes MBBS DFFP MRCGP
GP and SCMO in Family Planning
Martin Walling FRCGP FFSRH
GP and SCMO in Family Planning
Lincolnshire Primary Care Trust, UK
Stephen Killick MD FRCOG FFFP
Professor of Reproductive Medicine and Surgery, University of Hull and Hull York Medical School, UK
ABSTRACT
Background This study aims to explore the views
of women concerning their choice of long-acting
method of contraception.
Method Two-hundred and eighty-six women who
had either been sterilisedorfittedwith an etonorgestrel
(ETN) implant or the levonorgestrel intrauterine
system (LNG IUS) were invited to take part. A
response rate of 54% was achieved. Women from
all three groups reported positive and negative
experiences with their chosen method.
Results Women frequently choose sterilisation
specifically because it is irreversible, does not in-
volve hormonal treatment, and they do not wish to
retain choice of future fertility. Women incorrectly
regard sterilisation as more reliable than any revers-
ible method. Regret after sterilisation was common,
even if this was preceded by full counselling. Even
among patients of practices with a special interest
in family planning, long-acting methods, although
available, were not widely known about.
Conclusion This study suggests that women chose
sterilisation for one of three main reasons: to avoid
the possible side-effects of hormones; to avoid con-
tinually having to make decisions regarding child-
bearing; and/or a lack of information regarding
reversible methods. Sterilisation is often chosen by
women specifically because of its irreversibility. This
may explain why long-acting reversiblemethods have
remained relatively unpopular.
Keywords: contraception, long-acting reversible
(LARC) methods, sterilisation
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Introduction
The pattern of contraceptive use has changed little
in Britain over recent years.1 In 2005/2006, 74% of
women under 50 years were using at least one method
of contraception. The contraceptive pill was the most
popular method (24%) followed by the male condom
(21%) and sterilisation (21%) of either partner. Other
methods included the intrauterine contraceptive device
(IUCD) (5%), withdrawal (4%), and hormonal injec-
tion (3%). Less than 1% of women used the female
condom.1
Sterilisation is a popular choice of contraception
and has been shown to produce high (92% in one
study2) levels of satisfaction.However, failure rates are
not as low as might be expected. One study showed
that pregnancy occurred in 5.5 per 1000 women one
year after sterilisation, and in 18.5 per 1000 after ten
years.3 That failure can occur some years after the
procedure suggests that it is not simply governed by
the ability of the operator. As a procedure, sterilisation
is not without other complications, which are in the
region of 0.5% following a simple laparoscopy, and
this figure rises in cases of obesity, pelvic adhesions or
incidental disease.4
Regret after sterilisation is also a significant prob-
lem, particularly in younger women,5–8 and in women
whoare sterilisedwhileundergoing concurrentCaesarean
section,9 in couples who report conflict prior to the
procedure,10,11 and in women sterilised shortly after
making their initial request.12 Regret rates remain
significant even when there has been careful coun-
selling prior to surgery, and in these circumstances few
primary care trusts provide funding for either steril-
isation reversal or in vitro fertilisation (IVF).
The relatively heavy reliance on sterilisation is
somewhat surprising given the introduction of several
long-term reversible contraceptive methods that are
of at least equal efficacy and also have non-contracep-
tive benefits. Long-acting reversible methods are now
widely available, and recent guidelines in the UK
recommend that they should be included in infor-
mation offered to all women requiring contracep-
tion.13
The levonorgestrel intrauterine system (LNG IUS),
introduced in England in May 1995,14 has many
advantages. Failure rates are very low (less that 1%),15
it gives contraceptive cover for five years, is easily
reversible,16 and results in few, if any, systemic hor-
mone changes.17Other advantages include the reduction
of menstrual blood flow,18,19 and relief of dysmenor-
rhoea,20 which led to it being licensed as a treatment
for menorrhagia.21 However, only 1% of women who
require contraception choose the LNG IUS.1
The etonorgestrel (ETN) progestogen implant was
introduced in 1999. It gives three years’ contraceptive
cover, and although delivering a systemic dose of steroid,
has high efficacy,22 a low failure rate,23,24 and relatively
high continuation rates,25–27 which contribute to its
high cost-effectiveness.25,28 Recent studies demonstrate
that difficulties with insertion and removal seem to
have been overcome by the single rod system,29–31
although there can be difficulties in certain situations,
for example where the rod is non-palpable.32 Where
there has been evidence of failure, provider error has
been suggested and further training for insertion recom-
mended.33 The main side-effect is unpredictable vaginal
bleeding,29 which has been shown to be the most
common reason for discontinuation.24 Despite ectopic
pregnancy rates being low,30 the first case was reported
recently.34
How this fits in with quality in primary care
What do we know?
The pattern of contraceptive use has changed little in Britain over recent years, and sterilisation is one of the
most popular methods chosen. It is, however, not without its problems, including failure and regret in some
cases. In recent years, alternative long-acting methods, with the added benefit of being easily reversible, have
been introduced. Despite their benefits, in relation to sterilisation they remain relatively underused.
What does this paper add?
This study combined quantitative and qualitative methods to explore the views of women on their choice of
long-actingmethod of contraception. Participants described a number of reasons that helped to explain why
sterilisation is still a relatively popular choice of method, despite the recent emergence of alternative,
reversible long-acting methods of contraception. Participants described how they wished to refrain from
methods involving hormones. Some women opted for sterilisation specifically because of its irreversibility,
and this may help to explain its lasting popularity. Despite the participants being recruited from general
practices in which staff had a special interest in long-acting reversible contraception (LARC) methods, there
was evidence of a lack of awareness about them, suggesting the need for more information to allow fully
informed choices.
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As with the LNG IUS, a main benefit is that it is
easily reversible. One study showed that the main
reason for women to discontinue its use was a change
of mind about wanting more children,35 which serves
to illustrate the positive aspects of its reversibility.
The aim of this study was to explore the views of
women concerning choice of long-acting method of
contraception and, where applicable, reasons for dis-
continuing their chosen method.
Method
The study used both quantitative and qualitative
research methods to explore the reasons behind the
women’s chosen methods.
Quantitative component
A retrospective survey was conducted among three
groups of women in north Lincolnshire, England, who
requested long-term contraception during the two
calendar years 2003 and 2004.
Using records from threeGPpractices, a total of 286
women were identified from the three groups below
(the initial aim was to recruit 300 women: 100 from
each of the three groups; however, only 86 women
from the sterilisation groupwere eligible to participate
in the study, giving a total sample of 286):
. those who had been sterilised
. those who had been fitted with an ETN implant
(Implanon)
. those who had been fitted with the LNG IUS
(Mirena; other injectable methods with shorter
periods of effectiveness, were not included).
The GP practices were all similar in terms of socio-
demographic and geographic characteristics. They
were purposively selected, as their staff had a special
interest in family planning. It was felt that this would
increase the potential to explore the views of women
who had exposure to and experience of long-acting
reversiblemethods. Thepractices’ family planning teams
did the initial counselling. All professionals were family
planning-trained, experienced counsellors and keen to
promote long-acting contraceptivemethods.Althougha
convenience sample, all eligible women registered at
the given time period were included in the sampling
frame, and so it can be considered to be representative
of the total patient population meeting the inclusion
criteria in the three practices.
Participants were initially contacted by letter and
sent details of the study. Those who decided to take
part were asked to return the questionnaire by post.
Non-respondents were contacted again after six weeks.
The questionnaire included items about the decisions
behind their choice of contraceptive method, satisfac-
tion with their chosen method, how successful they
felt it to have been, and whether they had suffered any
side-effects.
Qualitative component
Although not generalisable in the way quantitative
studies are designed to be, the qualitative approach
places an emphasis on the depth and richness of data,
including subjective experience, that cannot be easily
quantified and allows insight into personal experi-
ences that are highly relevant to the user but often
remain unreported in the medical literature.36
There were two parts to the qualitative component:
a document review and a series of interviews, consent
for which was sought on the questionnaire.
Document review
The main purpose of this retrospective analysis of
general practice (GP) records was to allow compari-
sons between recorded reasons for method discon-
tinuation and the answers to specific questions in the
questionnaire. This provided a consistency check on
the quality of data collected.
Interviews
Twenty-four women were purposively selected for
qualitative interview: eight who had been sterilised;
eight using the LNG IUS; eight using ETN implant.
The interviews were conducted over the telephone
by two experienced interviewers (GI or SB), and were
tape-recorded and transcribed. A typical interview
took around 20minutes, and data were analysed using
the ‘framework’ method.37
Ethical issues
Ethics approval was gained from the North Lincoln-
shire Local Research Ethics Committee (LREC). Each
participant was fully informed of the implications of
taking part and their right to withdraw at any time
without affecting their futuremedical treatment. They
were reassured that all information was totally confi-
dential, individuals would not be identifiable in any of
the researchoutputs, anddatawouldbeanonymisedand
only analysed by the central members of the research
team. Each participant was then required to sign a con-
sent form to confirm that shewas happy to participate.
Results
The number of questionnaires posted and returned is
shown in Table 1. The overall response rate was 54%,
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with 111women agreeing to a scrutiny of theirmedical
notes and 56 of these women agreeing to personal
interview.
Figure 1 shows the age distribution of the women
in the three groups of contraceptive use. ETN implant
was a more popular choice among the younger age
groups, including those under 20 years of age, while
the LNG IUS increased in popularity with age, peaking
among those in the 30–39-year age group. Perhaps
most surprising was the relatively young age profile of
those women opting for sterilisation, with 40% being
in the 30–34-year age group.
Sterilisation
The age range, at time of procedure, of those women
who had been sterilised was 22–44 years (median age
34 years; interquartile range (IQR) 6.75). There was
evidence that wanting no more children was a dom-
inating factor in women’s decision to opt for sterilis-
ation. Some women seemed certain about this:
‘I was positive I wanted no more children.’ (authors’
emphasis)
‘I neverwant anymore children. I have five from9 years to
18 months.’ (authors’ emphasis)
The women were asked which methods they had used
previously and were also asked to identify which of a
list of methods they felt they had sufficient knowledge
about, prior to being sterilised (see Table 2; termin-
ology relating to name of contraceptive methods is
shown as used in the questionnaire; categories are not
mutually exclusive as respondents were asked to circle
as many as they wished). Interestingly, knowledge of
all long-acting methods, including sterilisation was
relatively low.
Reasons given for not considering other methods
included having tried thempreviously (some reported
negative experiences or reported that they simply didn’t
work), while others felt it was time for a more perm-
anent method or one that had no side-effects. Examples
of negative experiences with other methods are illus-
trated below:
‘Not interested in hormones contraception. Tried pill,
didn’t like it ... heard coil’s painful.’
‘Tried Mirena [IUCD] but it made me feel angry with the
world and on edge the whole time.’
Table 1 Response rates
Sterilisation ETN implant LNG IUS Total
Questionnaires posted (n) 86 100 100 286
Questionnaires returned (n) 47 48 60 155
Response rate (%) 55 48 60 54
Consent to notes scrutiny (n) 37 31 43 111
Consent to interview (n) 20 17 19 56
Figure 1 The age distribution for each of the three groups of women
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Two women reported that they were unaware of
alternative long-term methods, and only five said
they had considered other reversible methods.
Twenty-eight percent (n = 13) of the women
reported feeling regret at their decision to opt for
sterilisation. Seven reported feeling a little regret,
while six felt that they regretted their decision a lot.
Seventy-two percent, however, when asked if they felt
regret, replied ‘not at all’. Those reporting regret began
to feel this way shortly after the procedure (six women
up to three months after). One respondent when asked
to elaborate replied:
‘Before, during and after. It’s too final and takes your
options away.’
Even some of the women who reported feeling no
regret indicated later that they may in fact have had
some doubts. The following statement was from a
woman who initially replied ‘not at all’ to the question
on regret:
‘I sometimes wonder if I’ve missed out on family life, and
if I was selfish.’
Reasons for regretting sterilisation were varied. Some
related to marriage break up and starting a new rela-
tionship, or current children getting older. Others
indicated that they may have changed their minds
about not wanting any further children. Interestingly,
one woman who initially reported the fact that steril-
isation was ‘easy and final’ as her reason for opting for
it, described her reasons for regret as:
‘Thoughts of another baby and not having a choice any
more.’
Other women reported some physical discomfort:
‘Became apparent I can still feel the clips and sometimes it
is painful’
whilst one woman reported heavy painful periods,
which she had not suffered from previously. Another
reported feeling:
‘Very ill after op ... My periods have been so unbearable
since op. Pain worse than having baby.’
ETN implant (Implanon)
The age range of womenwith an ETN implant was 16–
48 years (median age 29 years; IQR 14.75). The main
reasons for opting for thismethod included ease of use
(n = 23), previous problems with other methods (n =
13), reliability (n = 7), long-term benefits (n = 6) and
that it was selected on the advice of the GP or nurse
(n = 4).
Eight (17%) of the women said they had considered
sterilisation, and this was not significantly different
Table 2 Previous use and knowledge of contraceptive methods among the women who had
been sterilised
What forms of contraception
have you used in the past?
% (n)
Before your sterilisation, which
of the following do you think
you had enough knowledge of?
% (n)
The pill 94.4 (34) 91.2 (31)
The mini-pill 16.7 (6) 29.4 (10)
Condoms 69.4 (25) 70.6 (24)
IUCD (coil) 8.3 (3) 26.5 (9)
Mirena 8.3 (3) 14.7 (5)
Norplant 5.6 (2) n/a
Implanon 8.3 (3) 5.9 (2)
Depo injections 25.0 (9) 23.5 (8)
Natural family planning methods 16.7 (6) 26.5 (9)
Sterilisation n/a 41.2 (14)
None of the above 0 (0) 5.9 (2)
aNorplant was withdrawn from the UK market in 1999
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between clinics (P = 0.57). Reasons for ultimately
opting against it related to feeling too young, possibly
wanting more children in the future, being talked out
of it, wanting to try an ETN implant first, it being too
permanent, and family experience of difficulties after
sterilisation, alongside not being able to spare the time
away from small children to undergo the procedure.
Thirty-one (65%) of the women reported both
physical and psychological side-effects from an ETN
implant. These included excessive or constant vaginal
bleeding (n = 15), mood swings or depression (n = 8),
pain or bloatedness (n = 6), irregular periods (n = 6),
weight gain (n = 5), headaches (n = 4), loss of libido
(n = 3), and amenorrhoea (n = 3). One or two women
also reported localised itching, breast tenderness, fatigue,
hair growth, acne and nausea.
Of the 48 women who returned a questionnaire,
13 reported that their ETN implant had since been
removed. One of these was not using any contracep-
tion as she was not sexually active. Of the remaining 12
women, four were now taking the combined pill and
one the progesterone only pill, two were using con-
doms, two were using the LNG IUS, and three were
using injectable contraception. None had gone on to
be sterilised.
Of those who had had their ETN implant removed,
four had done so less than 12 months after insertion,
five between 12 and 24 months, and one more that 24
months after insertion (three women did not answer
this question). Reasons for removal related mainly to
excessive or constant vaginal bleeding (sevenwomen).
Other reasons were to end suffering from headaches
and to increase libido.
LNG IUS (Mirena)
The age range of those women who had had an LNG
IUS coil inserted was 20–53 years (median age 34.5
years; IQR 10). Women were asked through qualitat-
ive entries on the questionnaire about the reason they
chose LNG IUS for contraception. The most popular
explanations were its ease and convenience of use
(especially not having to think about it every day),
and its resulting in ‘lighter periods’. Women also
reported its reliability and the fact that they were
aware of few side-effects as strong influences on their
choice. Others chose it because it was ‘long term’ and
because it was reversible.
Women were asked whether they had considered
sterilisation; 22% replied that they had (there were no
significant differences between clinics: P = 0.345), but
reasons for not opting for it centred around uncer-
tainty about never wanting to conceive in the future
(fourwomen), notwanting the additional risk of surgery
(three women), the LNG IUS resulting in less vaginal
bleeding (twowomen), being too young (threewomen),
or being advised against it for unspecified reasons (one
woman). One woman cited the one-year waiting time
for sterilisation as her reason for opting against it. One
woman felt that sterilisation:
‘does not offer any advantage over Mirena but has less
benefits (i.e. periods) and more risks.’
The pill was the most commonly cited previous contra-
ceptive method (97%), with condoms next (77%).
Interestingly, some women had previously also tried
other long-acting contraceptive methods: coil 23%,
injectable contraception 17%,Norplant 13%andETN
implant 10%.
Fifty-three per cent reported having suffered side-
effects from the LNG IUS (there were no significant
differences in numbers reporting side-effects by clinic
of insertion: P = 0.079), and these included irregular
bleeding (11%), abdominal or pelvic pain (6%), vaginal
discharge (4%), weight gain (3%), breast tenderness
(3%), nausea (2%), tiredness (2%) and mood swings
(2%).
Twenty-five per cent of the women had had their
LNG IUS removed at the time of data collection (there
were no significant differences by clinic of insertion:
P = 0.098), some for reasons unrelated to any side-
effects (such as their partner being sterilised or coming
to the end of five years of use). Other reasons for
removal included: ‘abdominal pain’ (n = 2), ‘felt ill
andwas suffering tingling in foot, hand and face’ (n=1),
‘infection/bleeding’ (n = 1), ‘treatment required fol-
lowing irregular smear test’ (n = 1). Three women
reported having it removed to try for another baby,
which highlights its use as a reversible method. Those
who had discontinued the LNG IUS were asked about
their current contraceptivemethod. Interestingly, two
had gone on to use an ETN implant but none had gone
on to be sterilised.
Discussion
This study provided insight intowhy the LNG IUS and
ETN implant are so rarely chosen as alternatives to
sterilisation despite their obvious advantages. It investi-
gated women’s decisions to opt for both sterilisation
andother long-acting contraceptivemethods.We looked
at the both influences behind their initial decisions and,
where applicable, the reasons behind their decisions to
discontinue their chosen method.
The response rate (54%) constituted a significant
limitation to this study, which could not therefore be
considered truly representativeof allwomenusing eachof
the contraceptive methods discussed, but nevertheless
provided valuable insight into the experiences of the
respondents.
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This study suggests that women chose sterilisation
for one of three main reasons: to avoid the possible
side-effects of hormones, to avoid continually having
to make decisions regarding childbearing, and/or a
lack of information regarding reversible methods.
In linewithother research, this study foundevidenceof
women regretting the decision to be sterilised,5–12 even
among those who felt very secure about their initial
decision. In addition, the study identified that steril-
isation was often chosen by women specifically because
of its irreversibility. This may explain why long-acting
reversible methods have remained so unpopular, even
inmedical practices where they are actively promoted.
Given the significant regret rates, further use of
reversible methods of contraception would seem to be
a desirable progression. This argument holds when we
consider the relatively high divorce rates in the UK (in
2007, at 2.7 per 1000 population, the UK had the third
highest divorce rate in western Europe38), which may
lead to the re-establishment of new relationships
and subsequent desire for more children. Addition-
ally, studies have shown that themain reason for regret
of sterilisation is later deciding that more children are
actuallywanted. The evidence suggests that despite feeling
confident at the time of decision making, sterilisation
may not be the best option for many women. More
research is required to explore the most viable methods
of raising awareness of valid alternatives to sterilis-
ation.
This study did show a surprising age distribution of
women opting for sterilisation, peaking among the
30–34-year age group,whowere relatively youngwomen
who might be more prone to changing their mind in
the future about desired family size. Nevertheless, this
study demonstrated that there was some knowledge
and awareness of long-acting reversible methods of
contraception in our study population.Wherewomen
reported experience of long-acting reversible methods,
positive experiences were heard from women using
both an ETN implant and the LNG IUS, although
neither was completely without problems and some
women did report side-effects.
Even among participants who were recruited from
specialist family planning practices, there was evidence
of a need for increased awareness about alternatives to
sterilisation. The sampling methods used here limited
the extent to which findings could be generalised, and
therefore a further study of women randomly selected
fromnon-specialist practices in the future, when long-
acting reversible methods have become more wide-
spread, would be informative. Of particular interest
would be the extent to which theNational Institute for
Health and Clinical Excellence (NICE) guidelines on
the use of long-acting reversible methods are being
implemented, and whether regret after sterilisation is
being reduced.13
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